Pharmagreen Biotech Inc.
PHBI
Other OTC0.00
USD
- -
- -
CIK
0001435181
ISIN
US71716C1099
CUSIP
71716C109
Return %
Stock
S&P500
1Y
-10.00
19.25
3Y
-28.00
65.11
5Y
-95.71
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Peter Wojcik
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2987 Blackbear Court Coquitlam BC Canada V3E 3A2
- IPO Date
- Aug 15, 2018
- CIK
- 0001435181
- Website
- pharmagreen.ca
- Similar Companies
- Business
- Pharmagreen Biotech Inc. (PHBI) operates as a biotechnology company focused on nutraceutical formulations and advanced plant tissue culture technologies in North America. The company develops and markets MaxGenomic supplement, a proprietary nutrigenomic blend of medicinal mushrooms and therapeutic plants including beta-glucans and lipopolysaccharides to support DNA repair, cellular health, mind, and body function; provides Chibafreen tissue culture services for disease-free starter plantlets using micro-propagation techniques; offers DNA testing for plant genetics verification; delivers live plant storage solutions; supplies consulting on plant genetic selection, standard operating procedures for cultivation, and preservation; and plans IoT greenhouses for cannabis nursery production along with live rosin cannabis concentrates. Headquartered in Coquitlam, British Columbia, Canada, with operations centered in Nevada, the company was incorporated in 2007. Recent developments include a January 2024 supply agreement with SierraSil Health Inc. for trademarked mineral complexes in nutraceutical formulations; October 2024 announcement of significant revenue potential from a major project estimated at up to $32 million by year three; September 2024 reaffirmation of non-toxic financing commitment amid progress on a foreign government collaboration; and ongoing business advancements in nutraceuticals beyond cannabis.
Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project
Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress
PHBI - Pharmagreen Signs Supply Contract and Trade Marked Name Use of SierraSil(R) in Its' Nutraceutical Formulations
Pharmagreen Provides Update on Funding and Acquisition Progress
Pharmagreen Signs MOU to Acquire a California Based Cannabis Company
Pharmagreen Provides Company Update For Its Shareholders
Pharmagreen Extends the Letter of Intent Timeline with Advanced Bio-Oil Technologies Ltd.
10 Penny Stocks That You Can Have for Less Than a Dime